Table 1.
Characteristics of the participating studies
| Study | Country | Design | Setting | No. (= 219575) | Year inclusion | PE, n (% within study) |
|---|---|---|---|---|---|---|
| Avon Longitudinal Study of Parents and Children7 | UK | Prospective cohort study | Population based | 13444 | 1991–92 | 317 (2.4) |
| Danish National Birth Cohort (DNBC)8 | Denmark | Prospective cohort study | Population based | 83532 | 1996–2002 | 2040 (2.4) |
| Finnish Genetics of Pre-eclampsia Consortium9 | Finland | Case-control study | Hospital based | 1930 | 2008–12 | 1049 (54.4) |
| Generation R Study (GenR)10 | The Netherlands | Prospective cohort study | Population based | 8363 | 2002–06 | 198 (2.4) |
| Lund Database (Lund) | Sweden | Prospective cohort study | Hospital based | 545 | 1999-–014 | 239 (43.8) |
| The Norwegian Mother and Child Cohort (MoBa)11 | Norway | Prospective cohort study | Population based | 98436 | 1999–2009 | 3721 (3.8) |
| Oslo Pregnancy Biobank (OPB)12 | Norway | Case-control study | Hospital based | 472 | 2001–13 | 182 (38.6) |
| Pregnancy Exposures and Preeclampsia Prevention Study (PEPP)13 | USA | Prospective cohort study | Population based | 4274 | 1999–2007 | 597 (14.0) |
| Prediction and Prevention of Pre-eclampsia Project (PREDO)14 | Finland | Prospective cohort study | Hospital based | 1032 | 2005–09 | 92 (8.9) |
| The Screening for Pregnancy Endpoints (SCOPE)15 | New Zealand, Australia, UK and Ireland | Prospective cohort study | Hospital based | 5573 | 2004–11 | 275 (4.9) |
| Vitamin C and Vitamin E in Pregnant Women at Risk for Pre-Eclampsia trial (VIP)16 | UK | Randomized clinical trial | Hospital based | 1974 | 2003–05 | 323 (16.4) |
Studies are listed in alphabetical order.
No., number of participants with a live-born singleton pregnancy between 22–43 weeks of gestation and complete information on the occurrence of pre-eclampsia (PE) and fetal sex.